Preventing New Human Immunodeficiency Virus Infections With Pre-exposure Prophylaxis
| Autor: | Karen Cotler, Charles Yingling, Cindy Broholm |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Advanced and Specialized Nursing medicine.medical_specialty Harm reduction Tenofovir business.industry Human immunodeficiency virus (HIV) virus diseases Primary care Primary care.nurse medicine.disease_cause Emtricitabine 030112 virology Food and drug administration 03 medical and health sciences Pre-exposure prophylaxis 0302 clinical medicine Medicine 030212 general & internal medicine business Intensive care medicine medicine.drug |
| Zdroj: | The Journal for Nurse Practitioners. 14:376-382 |
| ISSN: | 1555-4155 |
| DOI: | 10.1016/j.nurpra.2017.12.021 |
| Popis: | Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir (TDF/FTC) can reduce HIV infection risk by 92% in people at high risk for HIV. TDF/FTC was approved for HIV PrEP by the Food and Drug Administration in 2012. Primary care nurse practitioners (NPs) have not embraced this tool for the prevention of new HIV infection. A number of barriers exist that may prevent primary care NPs from prescribing HIV PrEP for patients in need. This article clarifies current recommendations for HIV PrEP and provides practical guidance for primary care NPs to incorporate this tool into their routine practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect